Innoviva's cash generation appears resilient, with operating cash flow holding between $35.3M and $54.5M per quarter from 2025Q4 to 2026Q3 and free cash flow margins of 35.5% to 43.1% in 2026.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$1.03-300.0% vs $0.52 | $106M-8.0% vs $115M |
Q3 2026 Aug 5, 2026 | $1.14+161.5% vs $0.44 | $120M+7.8% vs $111M |
Q2 2026 May 6, 2026 | $0.44+2.3% vs $0.43 | $98M-3.5% vs $102M |
Q1 2026 Feb 25, 2026 | $1.94+470.6% vs $0.34 | $115M+11.7% vs $103M |
Innoviva (INVA) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.08 per share a year ago.
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2026, and highlighted select corporate progress and achievements. “IST delivered anoth.
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today it will present data from four abstracts at IDWeek 2026, the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). The meeting will be held October 21–24, 2026, at the Walter E. Washington Conventio.
Investors need to pay close attention to INVA stock based on the movements in the options market lately.
Benchmark INVA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Innoviva, Inc. (INVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $50.33 | $100.84B | 17.69 | 4.11% | 12.96% | 23.31% | 3.23% | |
| $186.43 | $290.83B | 26.47 | 8.63% | 17.68% | 22.18% | 1.71% | |
| $42.61 | $50.41B | 99.63 | 4.31% | 2.94% | 6.35% | — | |
| $11.61 | $241.75M | -12.63 | -6.55% | -10.87% | -4.26% | — |
Innoviva, Inc. (INVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Innoviva, Inc. (INVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Aug 5, 2026·SEC
May 18, 2026·SEC
Get notified when INVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Innoviva, Inc. (INVA) stock FAQ — growth, dividends, profitability & financials explained
Innoviva, Inc. (INVA) reported $441.8M in revenue over the trailing twelve months. Revenue was $425.1M in fiscal year 2025. That is 272418% more than the $0.2M of fiscal year 2002.
Innoviva, Inc. (INVA) grew revenue by 13.7% over the trailing twelve months, compared with the twelve months before.
Yes. Innoviva, Inc. (INVA) earned $193.4M in net income over the trailing twelve months (a 43.8% net margin).
Innoviva, Inc. (INVA) had a return on equity (ROE) of 15.8% over the trailing twelve months. That is above the market's typical 10-15%.
Innoviva, Inc. (INVA) generated $181.4M in free cash flow over the trailing twelve months.
